1.Osman M, Wild A. “Spindle Cell Oncocytoma of the Anterior Pituitary Presenting with an Acute Clinical Course Due To Intraventricular Hemorrhage. A Case Report and Review of Literature,” American Journal of Case Reports, vol. 18, pp. 894–901.
2.Hu P, Huanhai L, Shuwei Z, et al. “Silencing of RASSF3 by DNA hypermethylation is associated with tumorigenesis in somatotroph adenomas,” PLoS One, vol. 8, no. 3, pp. e59024-.
3.Wang RQ, Lan YL, Lou JC, et al. “Expression and methylation status of LAMA2 are associated with the invasiveness of nonfunctioning PitNET,” Ther Adv Endocrinol Metab, vol. 10, p. 2042018818821296.
4.Asa SL, Ezzat S. “The pathogenesis of pituitary tumours,” Nat Rev Cancer, vol. 2, no. 11, pp. 836–849.
5.Yang Q, Li X. “Molecular Network Basis of Invasive Pituitary Adenoma: A Review,” Front Endocrinol (Lausanne), vol. 10, p. 7.
6.Scheithauer BW, Kovacs KT, Laws ER, Jr., Randall RV. “Pathology of invasive pituitary tumors with special reference to functional classification,” J Neurosurg, vol. 65, no. 6, pp. 733–744.
7.Priola SM, Esposito F, Cannavo S, et al. “Aggressive Pituitary Adenomas: The Dark Side of the Moon,” World Neurosurg, vol. 97, pp. 140–155.
8.Egeblad M, Werb Z. “New functions for the matrix metalloproteinases in cancer progression,” Nat Rev Cancer, vol. 2, no. 3, pp. 161–174.
9.Yin LL, Chung CM, Chen J, et al. “A suppressor of multiple extracellular matrix-degrading proteases and cancer metastasis,” J Cell Mol Med, vol. 13, no. 9B, pp. 4034–4041.
10.Wang J, Voellger B, Benzel J, et al. “Metalloproteinases ADAM12 and MMP–14 are associated with cavernous sinus invasion in pituitary adenomas,” Int J Cancer, vol. 139, no. 6, pp. 1327–1339.
11.Visse R, Nagase H. “Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry,” Circ Res, vol. 92, no. 8, pp. 827–839.
12.Rodríguez D, Morrison CJ, Overall CM. “Matrix metalloproteinases: What do they not do? New substrates and biological roles identified by murine models and proteomics,” BBA - Molecular Cell Research, vol. 1803, no. 1, pp. 39–54.
13.Gomis-Ruth FX, Maskos K, Betz M, et al. “Mechanism of inhibition of the human matrix metalloproteinase stromelysin–1 by TIMP–1,” Nature, vol. 389, no. 6646, pp. 77–81.
14.Cheng Y, Geng L, Zhao L, Zuo P, Wang J. “Human papillomavirus E6-regulated microRNA–20b promotes invasion in cervical cancer by targeting tissue inhibitor of metalloproteinase 2,” Mol Med Rep, vol. 16, no. 4, pp. 5464–5470.
15.Su CW, Su BF, Chiang WL, et al. “Plasma levels of the tissue inhibitor matrix metalloproteinase–3 as a potential biomarker in oral cancer progression,” International Journal of Medical Sciences, vol. 14, no. 1, pp. 37–44.
16.Shen B, Jiang Y, Chen YR, et al. “Expression and inhibitory role of TIMP–3 in hepatocellular carcinoma,” Oncol Rep, vol. 36, no. 1, pp. 494–502.
17.Kong L, Zhang P, Li W, et al. “KDM1A promotes tumor cell invasion by silencing TIMP3 in non-small cell lung cancer cells,” Oncotarget, vol. 7, no. 19, pp. 27959–27974.
18.Chen A, Liu S, Lu X, Wei L, Chen Y. “Inhibition of microRNA‑939 suppresses the development of human non‑small cell lung cancer via the upregulation of tissue inhibitor of metalloproteinases 2,” Mol Med Rep.
19.Adissu HA, McKerlie C, Di Grappa M, et al. “Timp3 loss accelerates tumour invasion and increases prostate inflammation in a mouse model of prostate cancer,” Prostate, vol. 75, no. 16, pp. 1831–1843.
20.Lin H, Zhang Y, Wang H, et al. “Tissue inhibitor of metalloproteinases–3 transfer suppresses malignant behaviors of colorectal cancer cells,” Cancer Gene Ther, vol. 19, no. 12, pp. 845–851.
21.Liu HY, Gu WJ, Wang CZ, Ji XJ, Mu YM. “Matrix metalloproteinase–9 and –2 and tissue inhibitor of matrix metalloproteinase–2 in invasive pituitary adenomas: A systematic review and meta-analysis of case-control trials,” Medicine (Baltimore), vol. 95, no. 24, p. e3904.
22.Guo H, Sun Z, Wei J, et al. “Expressions of Matrix Metalloproteinases–9 and Tissue Inhibitor of Metalloproteinase–1 in Pituitary Adenomas and Their Relationships with Prognosis,” Cancer Biother Radiopharm, vol. 34, no. 1, pp. 1–6.
23.Mao JH, Guo H, Si N, et al. “Regulating effect of MMP–9 and TIMP–1 in pituitary adenoma invasion,” Genet Mol Res, vol. 14, no. 4, pp. 17091–17098.
24.Lopez-Serra P, Esteller M. “DNA methylation-associated silencing of tumor-suppressor microRNAs in cancer,” Oncogene, vol. 31, no. 13, pp. 1609–1622.
25.Wei L, Chiu DK, Tsang FH, et al. “Histone methyltransferase G9a promotes liver cancer development by epigenetic silencing of tumor suppressor gene RARRES3,” J Hepatol, vol. 67, no. 4, pp. 758–769.
26.Nishida N, Nagasaka T, Nishimura T, et al. “Aberrant methylation of multiple tumor suppressor genes in aging liver, chronic hepatitis, and hepatocellular carcinoma,” Hepatology, vol. 47, no. 3, pp. 908–918.
27.Yi X, Guo J, Guo J, et al. “EZH2-mediated epigenetic silencing of TIMP2 promotes ovarian cancer migration and invasion,” Sci Rep, vol. 7, no. 1, p. 3568.
28.Cao J, Li Z, Yang L, Liu C, Luan X. “Association Between Tissue Inhibitor of Metalloproteinase–3 Gene Methylation and Gastric Cancer Risk: A Meta-Analysis,” Genetic Testing & Molecular Biomarkers, vol. 20, no. 8, p. 427.
29.Li X, Lu J, Teng W, Zhao C, Ye X. “Quantitative Evaluation of MMP–9 and TIMP–1 Promoter Methylation in Chronic Periodontitis,” DNA Cell Biol, vol. 37, no. 3, pp. 168–173.
30.van Kempen PM, van Bockel L, Braunius WW, et al. “HPV-positive oropharyngeal squamous cell carcinoma is associated with TIMP3 and CADM1 promoter hypermethylation,” Cancer Med, vol. 3, no. 5, pp. 1185–1196.
31.Maleva Kostovska I, Jakimovska M, Popovska-Jankovic K, et al. “TIMP3 Promoter Methylation Represents an Epigenetic Marker of BRCA1ness Breast Cancer Tumours,” Pathol Oncol Res, vol. 24, no. 4, pp. 937–940.
32.Hsu CH, Peng KL, Kang ML, et al. “TET1 suppresses cancer invasion by activating the tissue inhibitors of metalloproteinases,” Cell Rep, vol. 2, no. 3, pp. 568–579.
33.Celiker MY, Wang M, Atsidaftos E, et al. “Inhibition of Wilms’ tumor growth by intramuscular administration of tissue inhibitor of metalloproteinases–4 plasmid DNA,” Oncogene, vol. 20, no. 32, pp. 4337–4343.
34.Das AM, Bolkestein M, van der Klok T, et al. “Tissue inhibitor of metalloproteinase–3 (TIMP3) expression decreases during melanoma progression and inhibits melanoma cell migration,” Eur J Cancer, vol. 66, pp. 34–46.
35.Tofrizal A, Fujiwara K, Azuma M, et al. “Tissue inhibitors of metalloproteinase-expressing cells in human anterior pituitary and pituitary adenoma,” Med Mol Morphol, vol. 50, no. 3, pp. 145–154.
36.Dong sheng HE, Chen MZ, Wang HJ, et al. “Role of Matrix Metalloproteinases–9, 2 and Their Inhibitor-TIMP–1, 2 in Invasive Pituitary Adenomas Biological Behavior,” Chinese Journal of Cancer, vol. 21, no. 10, p. 1124.
37.Yun J, Mi HP, Dong JS, et al. “IL–32 gamma reduces lung tumor development through upregulation of TIMP–3 overexpression and hypomethylation,” Cell Death & Disease, vol. 9, no. 3, p. 306.
38.Wanga XZ, Gu JL, Gao M, et al. “Peperomin E Induces Promoter Hypomethylation of Metastatic-Suppressor Genes and Attenuates Metastasis in Poorly Differentiated Gastric Cancer,” Cell Physiol Biochem, vol. 50, no. 6, pp. 2341–2364.
39.Ma HS, Wang EL, Xu WF, et al. “Overexpression of DNA (Cytosine–5)-Methyltransferase 1 (DNMT1) And DNA (Cytosine–5)-Methyltransferase 3A (DNMT3A) Is Associated with Aggressive Behavior and Hypermethylation of Tumor Suppressor Genes in Human Pituitary Adenomas,” Medical Science Monitor International Medical Journal of Experimental & Clinical Research, vol. 24, pp. 4841–4850.